Bumetanide solution
Bumetanide solution is mainly composed of Bumetanide (HY-17468). Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 28395-03-1
- Fòrmula: C17H20N2O5S
- Peso molecular:364.42
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
Chemical Information
-
No. CAS 28395-03-1
-
Peso molecular 364.42
-
Fòrmula C17H20N2O5S
-
SMILES
O=C(C1=CC(NCCCC)=C(C(S(=O)(N)=O)=C1)OC2=CC=CC=C2)O
-
Synonyms
Ro 10-6338 solution; PF 1593 solution
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Lykke K, et al. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A. Epilepsy Behav. 2016 Jun;59:42-9. [Content Brief]
[2]. Ciaran Richardson, et al. Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and -independent pathways. J Cell Sci. 2011 Mar 1;124(Pt 5):789-800. [Content Brief]
[3]. Martha E O'Donnell, et al. Bumetanide inhibition of the blood-brain barrier Na-K-Cl cotransporter reduces edema formation in the rat middle cerebral artery occlusion model of stroke. J Cereb Blood Flow Metab. 2004 Sep;24(9):1046-56. [Content Brief]
[4]. S H Lee, et al. Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokinet Biopharm. 1994 Feb;22(1):1-17.6 [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)